MARKET

AYTU

AYTU

Aytu BioScience
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.010
0.000
0.00%
Opening 13:54 10/22 EDT
OPEN
1.000
PREV CLOSE
1.010
HIGH
1.010
LOW
0.9850
VOLUME
1.42M
TURNOVER
--
52 WEEK HIGH
2.990
52 WEEK LOW
0.3352
MARKET CAP
127.10M
P/E (TTM)
-1.9696
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Mid-Afternoon Market Update: Dow Surges 500 Points; CleanSpark Shares Plummet
Toward the end of trading Wednesday, the Dow traded up 1.80% to 28,272.86 while the NASDAQ rose 1.75% to 11,350.18. The S&P also rose, gaining 1.62% to 3,415.28.
Benzinga · 10/07 18:33
DDD, OCUL, AYTU and CLSK among midday movers
Gainers: The Peck Company (PECK) +67%.CVD Equipment (CVV) +56%.Sunworks (SUNW) +47%.Ocean Power Technologies (OPTT) +42%.ReneSola (SOL) +35%.Taiwan Liposome (TLC) +29%.Ocular Therapeutix (OCUL) +20%.Broadwind (BWEN) +19%.Chimerix (CMRX) +16%.3D Systems (DDD) +16%.Losers: Electro-Sensors (ELSE) -35%.Asia
Seekingalpha · 10/07 16:43
Mid-Day Market Update: Gold Falls 1%; Sunworks Shares Spike Higher
Midway through trading Wednesday, the Dow traded up 1.57% to 28209.00 while the NASDAQ rose 1.46% to 11,316.91. The S&P also rose, gaining 1.34% to 3,405.96.
Benzinga · 10/07 16:18
Ocular Therapeutix and American Well among healthcare gainers, ARCA biopharma and Axovant Gene Therapies among losers
Gainers: Taiwan Liposome (TLC) +36%. Ocular Therapeutix (OCUL) +21%. LogicBio Therapeutics (LOGC) +11%. American Well (AMWL) +11%. Tiziana Life Sciences (TLSA) +11%.Losers: Enlivex Therapeutics (ENLV) -12%. Aytu BioScience (AYTU) -12%. Xtant Medical (XTNT) -11%.
Seekingalpha · 10/07 14:54
DKNG, GH leads premarket losers' pack
Electro-Sensors (ELSE) -24%.CleanSpark (CLSK) -24% after pricing equity offering.Asia Pacific Wire & Cable (APWC) -17%.RCM Technologies (RCMT) -13%.Ashford Hospitality Trust (AHT) -12% after shareholders OK issuance of up to 126M shares.Aytu BioScience (AYTU) -11% erasing yesterday's
Seekingalpha · 10/07 12:34
The Daily Biotech Pulse: Bristol-Myers Squibb's Lung Cancer Readout, Positive News From Masimo, Integra Lifesciences
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)
Benzinga · 10/07 11:30
Recap: Aytu BioScience Q4 Earnings
Shares of Aytu BioScience (NASDAQ:AYTU) fell 6.77% after the company reported Q4 results.Quarterly Results Earnings per share rose 98.46% over the past year to ($0.02), which beat the estimate of ($0.03).Revenue of $14,861,000 rose by 766.03% from the same period last year, which beat the estimate of
Benzinga · 10/06 21:37
Aytu BioScience EPS beats by $0.01, beats on revenue
Aytu BioScience (AYTU): Q4 GAAP EPS of -$0.03 beats by $0.01.Revenue of $14.86M (+764.0% Y/Y) beats by $3.62M.Shares +19.55%.Press Release
Seekingalpha · 10/06 20:07
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AYTU. Analyze the recent business situations of Aytu BioScience through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AYTU stock price target is 2.625 with a high estimate of 3.000 and a low estimate of 2.250.
EPS
Institutional Holdings
Institutions: 89
Institutional Holdings: 11.41M
% Owned: 9.07%
Shares Outstanding: 125.84M
TypeInstitutionsShares
Increased
17
5.77M
New
48
1.30M
Decreased
7
394.40K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.20%
Pharmaceuticals & Medical Research
+0.14%
Key Executives
Chairman/Chief Executive Officer/Director
Joshua Disbrow
Chief Financial Officer/Treasurer/Secretary
David Green
Chief Operating Officer
Jarrett Disbrow
Executive Vice President
Matthew Phillips
Director
Steven Boyd
Director
Ketan Mehta
Independent Director
Gary Cantrell
Independent Director
Carl Dockery
Independent Director
John Donofrio
Independent Director
Michael Macaluso
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AYTU
Aytu BioScience, Inc. is a specialty pharmaceutical company. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. The primary care portfolio includes Natesto, the nasal formulation of testosterone for men with hypogonadism, ZolpiMist, the oral spray prescription sleep aid, and Tuzistra XR, the 12-hour codeine-based antitussive syrup. The pediatric portfolio includes AcipHex Sprinkle, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; Cefaclor, a second-generation cephalosporin antibiotic suspension; Karbinal ER, an extended-release carbinoxamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aytu Bioscience Inc stock information, including NASDAQ:AYTU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AYTU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AYTU stock methods without spending real money on the virtual paper trading platform.